Tumor susceptibility and apoptosis defect in a mouse strain expressing a human p53 transgene

Cancer Research

Volumn 66, Issue 6, 2006, Pages 2928-2936

  Dudgeon, Crissy ^a   Kek, Calvina ^b   Demidov, Oleg N ^b   Saito, Shin Ichi ^a   Fernandes, Kenneth ^c   Diot, Alexandra ^c   Bourdon, Jean Christophe ^c   Lane, David P ^b   Appella, Ettore ^a   Fornace Jr , Albert J ^a,d   Bulavin, Dmitry V ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIDAZOLINE DERIVATIVE; NUTLIN 3A; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CARCINOGENICITY; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CENTROSOME; CONTROLLED STUDY; DNA DAMAGE; GENE EXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; GENOTOXICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION; TRANSCRIPTION REGULATION; TRANSGENE; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; TRANSGENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33645521202     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2063     Document Type: Article

References (39)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
2. Woods DB, Vousden KH. Regulation of p53 function. Exp Cell Res 2001;264:56-66.
3. Manfredi JJ. p53 and apoptosis: it's not just in the nucleus anymore. Mol Cell 2003;11:552-4.
4. Pietenpol JA, Stewart ZA. Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology 2002; 181-182:475-81.
5. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996;10:1054-72.
6. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
7. Johnson TM, Hammond EM, Giaccia A, Attardi LD. The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nat Genet 2005;37:145-52.
8. Mihara M, Erster S, Zaika A, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003;11:577-90.
9. Chipuk JE, Kuwana T, Bouchier-Hayes L, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004;303: 1010-4.
10. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-21.
11. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7.
12. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003;10:431-42.
13. Tarapore P, Fukasawa K. Loss of p53 and centrosome hyperamplification. Oncogene 2002;21:6234-40.
14. Koch-Paiz CA, Momenan R, Amundson SA, Lamoreaux E, Fornace AJ. Estimation of relative mRNA content by filter hybridization to a polyuridylic probe. Biotechniques 2000;29:706, 708, 712, 714.
15. Takai H, Naka K, Okada Y, et al. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J 2002;21:5195-205.
16. Boley SE, Wong VA, French JE, Recio L. p53 heterozygosity alters the mRNA expression of p53 target genes in the bone marrow in response to inhaled benzene. Toxicol Sci 2002;66:209-15.
17. Reisman D, Greenberg M, Rotter V. Human p53 oncogene contains one promoter upstream of exon 1 and a second, stronger promoter within intron 1. Proc Natl Acad Sci U S A 1988;85:5146-50.
18. Dumont P, Leu JI, Della PAC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-65.
19. Bourdon JC, Fernandes K, Murray-Zmijewski F, et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005;19:2122-37.
20. Garcia-Cao I, Garcia-Cao M, Martin-Caballero J, et al. "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J 2002;21:6225-35.
21. Kemp CJ, Wheldon T, Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet 1994;8:66-9.
22. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-9.
23. Schmitt CA, Fridman JS, Yang M, et al. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002;1:289-98.
24. 2-M promoters. Mol Cell Biol 2005; 25:3737-51.
25. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8.
26. Luo JL, Yang Q, Tong WM, et al. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 2001;20:320-8.
27. Luo JL, Tong WM, Yoon JH, et al. UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin. Cancer Res 2001;61:8158-63.
28. Liu Z, Hergenhahn M, Schmeiser HH, et al. Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc Natl Acad Sci U S A 2004;101:2963-8.
29. Liu Z, Muehlbauer KR, Schmeiser HH, et al. p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. Cancer Res 2005;65:2583-7.
30. 23. EMBO J 2004;23:3689-99.
31. 20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J 1999;18:1805-14.
32. 18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem J 1999;342:133-41.
33. Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci U S A 1999;96:13777-82.
34. Mendrysa SM, McElwee MK, Michalowski J, et al. mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 2003;23:462-72.
35. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993;7: 1126-32.
36. Jeffers JR, Parganas E, Lee Y, et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003;4:321-8.
37. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001;7:673-82.
38. Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 2003;100: 1931-6.
39. Liu G, Parant JM, Lang G, et al. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 2004;36:63-8.